


Outcomes that work - improving end of life experience for patients and providers while reducing funder waste


Alignd is a value based care company with an end-to-end serious cancer / palliative care product as first working example.

1612 patients have been or are under care since Alignd started in Aug 2019.

Future developments in chronic kidney disease and maternity are under consideration.



ALIGND'S INTENTIONAL SOLUTION DESIGN



Alignd used a risk-adjustment methodology to calculate results (considering the underlying health status and health spend of the patients when looking at their overall health care outcomes and/or health care costs). Alignd further compared the risk-adjusted results to a propensity-score case-matching methodology. Case matching was used to overcome the problems associated with small sample sizes as well as the imbalances in cohort sizes.

2022: RESULTS AT SCALE

This analysis for the 1,004 patients analysed in 2021 used both the risk-adjustment and case-adjustment methodologies separately, and demonstrated that the two methods produce comparable results. 79.3% of Alignd patients die at home or in a hospice.

Results were maintained when analysing 2022 data, with a larger pool of patients as seen in the infographic.



PROM



PREM

Alignd patients are compared to other oncology patients qualifying for palliative care.

Less non-beneficial surgery and chemo in last month of life


63% deaths at home / hospice

47.5% less chemo
50.2% less surgery


4 / 5 Experience of care

R119k savings p/p

Alignd did not find a complete list of relevant ICHOM measures, but built on the ICHOM application of PROMs and PREMs. Clearly defining the right measures in close collaboration with the providers at the coalface and generating the data is key.



PROM / Process measure




Cost measure

At 50, Margaret had metastatic breast cancer. She was divorced, with two children, aged 16 and 20.



She underwent surgery, radiotherapy and two intense courses of chemotherapy over a 12-month period. But her cancer didn't respond to the chemotherapy as expected. Her oncologist suggested third line chemotherapy, although she would have to pay a significant amount from her own pocket for the treatment, as her oncology benefit on her medical aid was depleted. But Margaret was getting weaker and struggling with severe pain, and she had to stop working.

Margaret's cancer journey without Alignd



At 60, Solly was diagnosed with terminal lung cancer.



Solly's cancer journey on medical aid with an Alignd-partnered scheme

Solly underwent surgery to alleviate some of his symptoms. Doctors recommended chemotherapy with a long-term in-hospital plan. Solly did not want to spend his final days in hospital. He chose to receive home-based care that helped him remain comfortable. He was surrounded by his family in his last days.

